The immuno-oncology therapy developer's investors include UC’s office of the chief investment officer, which contributed to a $300m round in January.

US-based cancer drug developer Allogene Therapeutics has filed for a $100m initial public offering that will enable University of California (UC)’s office of the chief investment officer to exit. Allogene is working on genetically engineered allogeneic T cell medicines designed to kill cancer cells. The therapies will be based on cells taken from healthy donors,…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.